EX-99.1 2 ef20079469_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update - Total Company Revenues of $425.5 Million for the Second Quarter of 2026 - - BRINSUPRI® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026 - - ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $116.3 Million for the Second Quarter of 2026, Reflecting 8% Growth Over the Second Quarter of 2025 - - Company Raises 2026 BRINSUPRI Revenue Guidance to $1.25 Billion to $1.40 Billion - - Company Reiterates 2026 ARIKAYCE Revenue Guidance of $450 Million to $470 Million - - Company Raises Peak Revenue Estimate for its Three Lead Programs to More than $14 Billion Total - - Peak Revenue Estimate Consists of More than $7 Billion for BRINSUPRI, More than $6 Billion for TPIP, and More than $1 Billion for ARIKAYCE - BRIDGEWATER, N.J., August 6, 2026 - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today report…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Insmed Incorporated
INSMNASDAQEQUITYCurrent
Results of Operations and Financial Condition
ITEM 2.02 Results of Operations and Financial Condition. On August 6, 2026, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 pursuant to this Item 2.02.…
Company context
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines - including two approved therapies to treat chronic, debilitating lung diseases - as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Current securities
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Filed exhibits (2)
EX-99.2 3 ef20079469_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 August 6, 2026 Second-Quarter 2026 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to continue to successfully commercialize ARIKAYCE® in the U.S., Europe or Japan or failure to successfully commercialize BRINSUPRI® in the U.S. or Europe, or to maintain U.S., European or Japanese approval for ARIKAYCE or U.S. or European approval for BRINSUPRI; our inability to obtain full approval of ARIKAYCE from the FDA, or our failure to obtain regulatory approval to expand ARIKAYCE’s indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for our p…
Open exhibit ↗